Marketing HPV Vaccines: Fear of Cancer Didn’t Work – Will Fear of STD’s?

May 14, 2013 By Leave a Comment
False Evidence Appearing Real?

[SaneVax: Attempts to manufacture fear of cervical cancer was not enough to convince more than 20% of eligible adolescent girls in the U.S. to submit to HPV vaccines. According to a new 'study' perhaps fear of contracting an STD will change that.  The SaneVax team issues a warning to medical consumers: Do not be fooled by new [...]

[Continue reading...]
Filed Under: HPV, United States, Vaccine Marketing Tagged With: ,

SaneVax response to journal article promoting proposed nine-valent HPV vaccine

May 8, 2013 By Leave a Comment
IAC-logo

[Sanevax: The following letter to the editors of Infectious Agents and Cancer was submitted as a response to "Potential impact of a nine-valent vaccine in human papillomavirus related cancers," by Sylvia de Sanjosé, et al. After peer-review and approval, the letter was published in this month's edition of Infectious Agents and Cancer.] Dear Editors In Chief: The article entitled [...]

[Continue reading...]
Filed Under: HPV, SANE Vax in the News, United States, Vaccine Marketing Tagged With: ,

Dr. Elmar Joura on the next generation HPV vaccines: Is your conflict of interest showing?

May 6, 2013 By Leave a Comment
Conflicts of Interest?

[SaneVax:   The following article quotes Dr. Elmar Joura of the University Department of Gynaecology at the MedUni ViennDr as saying,  "There is data showing it is effective up to the 45th year of life." REALLY ??? The SaneVax team wants to know where he got this data, particularly when this is what the CDC has to say about [...]

[Continue reading...]
Filed Under: HPV, Vaccine Marketing, World News Tagged With: ,

Gardasil: Australia takes the lead, the story behind the headlines

May 1, 2013 By Leave a Comment
vaccine science?

By Elizabeth Hart The Gardasil HPV vaccine was originally rejected by the Australian Pharmaceutical Benefits Advisory Committee (PBAC) in 2006, when the Howard Liberal Government was in power. An article by Matthew Stevens in The Australian at the time (November 2006),(1) reports the PBAC rejected Gardasil because it was: “too expensive and, just maybe, not what [...]

[Continue reading...]
Filed Under: Australia, Australian Concerns, HPV, Vaccine Marketing, Vaccine Politics/People

HPV Vaccine Coming Soon to Trinidad and Tobago

February 4, 2013 By Leave a Comment
2 shots as good as 3?

[SaneVax: Despite the worldwide controversy surrounding the safety, efficacy and need for HPV vaccines, Trinidad and Tobago have agreed to purchase and use Gardasil in their country.  Is this a result of sound decision making, or good marketing?] The truth about HPV and Gardasil By Dr. Noel Kalicharan A few weeks ago, Health Minister Dr Fuad [...]

[Continue reading...]
Filed Under: Gardasil / Silgard, Trinidad/Tobago, Vaccine Marketing Tagged With: ,

Pharma using fear to market Rotavirus vaccines in India?

January 11, 2013 By Leave a Comment
Rotavirus Vaccine: Another market out of thin air?

[SaneVax: Where does one draw the line between public service announcements and marketing vaccines? Has GlaxoSmithKline made an attempt to duplicate Merck's success with Gardasil by creating another market out of thin air? At least some medical professionals in India believe that is exactly what is going on. It seems once death is associated with any particular [...]

[Continue reading...]
Filed Under: India, Rotavirus Vaccines, Vaccine Marketing Tagged With: , ,

CIDRAP Report on Flu Vaccines: Take a closer look

November 30, 2012 By Leave a Comment
wasted-money-2

[SaneVax: Upon close examination of 12,000 documents dating back to 1936, CIDRAP (Center for Infectious Disease Research & Policy) declared that seasonal flu vaccines have been 'over-promoted' and a 'waste of taxpayer money.' Is this a plea to stop vaccine fraud, or simply a blatant effort to flush more money down the proverbial pharmaceutical toilet? Medical [...]

[Continue reading...]
Filed Under: Seasonal Flu, United States, Vaccine Marketing Tagged With: ,

Are flu vaccines over-rated?

November 30, 2012 By Leave a Comment
Vaccine Debate

[SaneVax: Every year people line up to take their annual flu shot. Others have to literally fight for their right to choose as the vaccine debate rages on. Have flu vaccines been over-rated at the expense of public health? Have people been taking an unnecessary risk of side effects in the name of public health for [...]

[Continue reading...]
Filed Under: Seasonal Flu, United Kingdom, Vaccine Marketing Tagged With: ,

Flu Vaccines: Do the benefits outweigh the risks?

November 25, 2012 By Leave a Comment
Vaccine Debate

[SaneVax: Multiple studies have recently been released questioning the efficacy of annual flu vaccines. Despite this fact, the CDC is now promoting flu vaccines for pregnant women, children above the age of six months and everyone else, every year. Does this make medical sense or is it simply good marketing of vaccines? What is wrong with [...]

[Continue reading...]
Filed Under: Influenza Vaccines, United States, Vaccine Marketing Tagged With: ,

Vaccines: How much revenue is generated by the top sellers?

October 3, 2012 By Leave a Comment
Protection or profit?

[SaneVax: Governments around the world invest billions in vaccines every year. Ostensibly, this expenditure is all to protect human health and safety. Read the article below to understand exactly who benefits from vaccine revenues.] 20 Top-selling Vaccines – 2012 By Alison Bryant, Fierce Vaccines Data on the biggest-selling vaccines helps us understand what’s driving growth in the [...]

[Continue reading...]
Filed Under: Vaccine Marketing, Vaccines, World News Tagged With: ,